Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

INCLUSION CRITERIA: Histological diagnosis of non-MSI-H/pMMR CRC • Subjects who have biology-proven non-MSI-H/pMMR CRC and with radiographic findings suggestive of liver metastases may be eligible. Resectable liver metastases including: * synchronous liver metastases (present at the time of diagnosis of MSS CRC) and treatment-naïve * metachronous liver metastasis (developed after resection of the primary tumor) without prior adjuvant chemotherapy * metachronous liver metastasis (developed after resection of the primary tumor) with adjuvant chemotherapy completed greater than 3 months from the time of consent. Surgical candidate for resection Age ≥ 18 years. Rationale: Because no dosing or adverse event data are currently available on the use of dupilumab in combination with toripalimab in subjects \<18 years of age, children are excluded from this study. ECOG Performance Status 0-1 (Karnofsky ≥60%,) • Subjects with performance status \>1 carrying long-term disability (such as cerebral palsy) where the disability is not acute nor progressive, and unlikely to significantly affect their response to therapy may be enrolled at the investigator's discretion Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception upon study entry, for the duration of study participation, and for 3 months following completion of therapy. * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, …